In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Oct 13, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging technique using a substance called [68Ga]-pentixafor to help doctors see certain types of blood cancers and solid tumors more clearly. The main goal is to find out how well this imaging agent works in patients with conditions like Non-Hodgkin lymphoma, multiple myeloma, and specific histiocytic neoplasms, which are types of blood cancers. The trial is currently looking for 20 participants aged 18 and older who have been diagnosed with these cancers and have not received treatment yet or have not responded to previous treatments.

If you or a loved one are interested in participating, you’ll need to meet certain criteria, such as having a specific type of Non-Hodgkin lymphoma or a histiocytic neoplasm. Participants will undergo PET/CT scans to see how well the imaging agent is taken up by the body, which can help doctors understand more about the disease. It’s important to note that women who can become pregnant will need to take a pregnancy test before joining the study. Overall, this trial is an early-phase study, meaning it’s one of the first steps in testing this new imaging approach to improve cancer diagnosis and treatment planning.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:
• • Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria
• • or
• • Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD)
• • MGUS/SMM or MM according to IMWG definitions
• • Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with Cushing's disease.
• • Age ≥18
• • Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \& Guidelines) from assays obtained \<2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention
• • MSKCC patients
• Exclusion Criteria:
• • Breast-feeding
• • History of renal functional disorders (chronic kidney disease with eGFR\<30)
• • Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)